about
The hypercoagulable state of malignancy: pathogenesis and current debatePlatelet granule secretion continuously prevents intratumor hemorrhage.A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery.Hematology in palliative medicine.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalEtiology and consequences of thrombosis in abdominal vessels.Concomitant and antecedent deep venous thrombosis and cancer survival in male US veteransBreast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Cancer and venous thromboembolism: scope of the problem.The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.Splanchnic vein thrombosis in the mediterranean area in childrenHypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.Diffuse Arterial Thrombosis as a First Manifestation of Occult Malignancy.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Evaluation of anticoagulation selection for acute venous thromboembolism.Expression and shedding of endothelial protein C receptor in prostate cancer cells.Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.Systemic chemotherapy interferes in homocysteine metabolism in breast cancer patients.Distal Medullary Canal Decompression in Long Stem Hip Replacement in Long Bone Metastasis: Does it Reduce Cardiopulmonary Complications?Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency.Hypoproteinemia as a prognostic risk factor for arteriovenous fistula failure.Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period.Awareness regarding venous thromboembolism among internal medicine practitioners in Mexico: a national cross-sectional study.Anticoagulant Therapy in Oncologic Patients Undergoing Venous Stenting for Superior Vena Cava Syndrome and Other Interventional Procedures
P2860
Q28212265-BF180F4D-27F2-4260-AB64-F0773E2F429FQ30483704-4B593E19-F90E-41C9-9D90-B3894CDCF088Q33305170-17FA1E88-4506-4D26-ADAB-C7C1DF631E12Q33364223-B1A376B4-0B4D-4C91-9440-CC3E99C127B3Q33561203-026D1862-9B79-4F7C-A40F-076DCB4FF1ECQ34013126-7FC86B1F-0B06-4132-AFF4-F163E4B7175FQ35110789-808FC2C9-1EA4-48A4-8EB9-5AC073A9424FQ35490056-50198E49-6565-430B-8FE9-D51DD4776E7DQ36265569-47D3D1A9-FC9C-40D3-AD84-62DF4CE6B80DQ36598768-7C66D3E7-AF59-4AC8-AFBD-E35B0EFF0928Q37922590-B00E1534-337B-4085-A5F3-A03405B9E1F5Q38058380-A12F1157-68A9-4059-9B53-4989225DE850Q38995634-1E91215B-35DB-4F7C-9095-7BB6138F8270Q39137457-AD679D99-3409-49D8-B654-7A84FDCCAFEFQ39424848-8328621E-43B6-4A91-B163-445CEC84C354Q42239302-DF305DA2-21C0-46BB-AF5C-199BB4EBB469Q44197966-369BD6B4-919F-4A6B-BE96-2B8060B173ABQ44591661-62138BBC-3472-4370-9B38-05AAE43325FDQ49418085-4A0253C2-20B5-48FE-8DBF-423ACDDAAA82Q50109447-753A6110-0254-4AB7-A293-AB3691C8C037Q50925572-3518C2C1-23FB-499E-97D3-13379C97F5D9Q50990931-1BEEEB08-BE5D-42E9-97BC-ACB28E463728Q53186929-102D3EE3-0725-4549-86DB-60E8663DA741Q57269591-D472051D-33AA-425F-9CAE-B262BCA785E9
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Hypercoagulability in cancer.
@en
type
label
Hypercoagulability in cancer.
@en
prefLabel
Hypercoagulability in cancer.
@en
P1476
Hypercoagulability in cancer.
@en
P2093
Silverstein RL
P304
P356
10.1016/S0889-8588(05)70349-X
P577
1996-04-01T00:00:00Z